AstraZeneca shares seen slipping 3% after reported Bristol Myers talks
AstraZeneca shares are expected to drop up to 3% on Monday following reports of preliminary talks with Bristol Myers Squibb about a possible combination.
- Country:
- United States
AstraZeneca shares are expected to drop up to 3% on Monday, according to traders, after reports that the European pharmaceutical giant held preliminary talks about a possible combination with U.S.-based Bristol Myers Squibb.
ALSO READ
-
European shares start August higher on US-Iran diplomacy hopes
-
AstraZeneca shares tumble 7% after reported Bristol Myers talks
-
PRESS DIGEST-Financial Times - August 3
-
Apple set to lose nearly $500 billion in value after weak forecast
-
European stocks hit record high on tech, earnings boost; eye monthly gain
Google News